We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Confirms Volume Biomarker for Use in Kidney Disease Studies
FDA Confirms Volume Biomarker for Use in Kidney Disease Studies
The FDA confirmed the use of total kidney volume measurements in selecting patients for clinical trials in autosomal dominant polycystic kidney disease.